
Opinion|Videos|January 13, 2025
Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Other antibody-drug conjugates have been examined in the relapsed/refractory follicular lymphoma (R/R FL) space in combination with rituximab.
- Polatuzumab vedotin + rituximab and pinatuzumab vedotin + rituximab. In the R/R FL population, how do these agents perform?
- Given the data update from Alderuccio et al. ASH 2024, comment on how loncastuximab + rituximab could play a role in the treatment landscape for R/R FL. What patient considerations are critical to note?
Advertisement
Related to this article

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
